FindTrial
Sign In

Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01269905
Enrollment
Unknown
Registered
2011-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2011-01-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anticoagulation, Mechanical Heart Valve Replacement

Brief summary

The optimal valve substitute for patients between 60-70 years is controversial. We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.

Interventions

None listed

Sponsors

Johann Wolfgang Goethe University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* heart valve replacement

Exclusion criteria

* CABG * Afib

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026